Is Moderna Stock Overvalued?

1 min read

Moderna (NASDAQ: MRNA) ranks as one of the biggest winners of the coronavirus vaccine race. The stock has skyrocketed, but has it gone up too much? In this Motley Fool Live video recorded on Jan. 6, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss whether or not Moderna is overvalued after its impressive run.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Here’s Why General Motors Is the Only EV Stock I’ll Buy

Next Story

Nikola Secures Energy Partner for Hydrogen Production

Latest from Blog